Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16

Benzinga Newsdesk www.benzinga.com Positive 78.1%

Neg 0% Neu 0% Pos 78.1%

Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.